<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030679</url>
  </required_header>
  <id_info>
    <org_study_id>19DM05L</org_study_id>
    <nct_id>NCT01030679</nct_id>
  </id_info>
  <brief_title>Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus</brief_title>
  <official_title>To Investigate the Glycemic Control and Lipid Profile of CKD-501 Monotherapy in Patients With Type 2 Diabetes Mellitus:a Eight-week, Multicenter, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-ranging Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501
      compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes
      for 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fasting plasma glucose at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Glycemic parameters after 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Lipid parameters after 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile after 8 weeks of treatment</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>CKD-501 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-501 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-501 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501 0.5mg</intervention_name>
    <description>0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks</description>
    <arm_group_label>CKD-501 0.5mg</arm_group_label>
    <other_name>Lobeglitazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501 1mg</intervention_name>
    <description>1 mg/tablet, orally, 1 tablet once daily for 8 weeks</description>
    <arm_group_label>CKD-501 1mg</arm_group_label>
    <other_name>Lobeglitazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501 2mg</intervention_name>
    <description>2 mg/tablet, orally, 1 tablet once daily for 8 weeks</description>
    <arm_group_label>CKD-501 2mg</arm_group_label>
    <other_name>Lobeglitazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally, 1 tablet once daily for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type Ⅱ diabetes mellitus

          -  Fasting Plasma Glucose(FPG)≥ 126 and ≤ 270

          -  HbA1c between 7 and 11%

          -  Body mass index (BMI) in the range 21-40

          -  The patients who has been taking oral hypoglycemic agent or diet therapy before
             minimum 1 month

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Type I diabetes, gestational diabetes or secondary diabetes

          -  Treatment with insulin(over 1month) within 3 months

          -  Fasting Plasma Glucose level is over 270 mg/dl

          -  Triglyceride level is 500 mg/dl and over

          -  Uncontrollable hypertension

          -  History of myocardial infarction, heart failure, cerebral infarction, hematencephalon
             or unstable angina within 6 months

          -  Severe hepatic dysfunction: AST, ALT, Total bilirubin, ALP level over or equal to 3
             times as high as upper normal limit(UNL)

          -  Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal
             limit

          -  Needs treatment for acute disease, uncontrolled other diseae or diabetic complications

          -  In treatment concomitant drug having severe risk drug interaction with investigational
             drug

          -  History of cancer within 5 years

          -  History of drug abuse or alcoholism

          -  Hepatitis B Antigen(HBsAg) test is positive

          -  Treatment systemic or inhalant corticosteroids within 1 month prior to Screening

          -  Patient who have experience such as hypersensitivity reaction, serious adverse event
             or no effect by treatment with glitazones

          -  Fertile women who not practice contraception with appropriate methods Pregnant women
             or nursing mothers

          -  Has a contraindication to treatment investigational drug from the medical and
             psychogenic side

          -  Participated in other trial within 4 weeks Participating in other trial at present

          -  An impossible one who participates in clinical trial by legal or investigator's
             decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongseop Choi, MD.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Inje University Medical Center</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chtholic University of Korea Uijeongbu St. Mary's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Seoul National Univertisy Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wonju Christian Hospital</name>
      <address>
        <city>Kangwon-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Inje University Sanggye-Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <last_update_submitted>December 14, 2009</last_update_submitted>
  <last_update_submitted_qc>December 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chin Kim/Medical Director</name_title>
    <organization>Chong Kun Dang</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus, type 2</keyword>
  <keyword>Glitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

